Tafinlar OverviewDabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma. Approvals and indications The Food and Drug...
Read more Tafinlar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dabrafenib
Recent Tafinlar Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 50mg, 75mg
NDC Database Records for Tafinlar: (4 results)Sorted by National Drug Code
- 0078-0681 Tafinlar 75 mg Oral Capsule by Novartis Pharmaceuticals Corporation
- 0078-0682 Tafinlar 50 mg Oral Capsule by Novartis Pharmaceuticals Corporation
- 0173-0846 Tafinlar 50 mg Oral Capsule by Glaxosmithkline LLC
- 0173-0847 Tafinlar 75 mg Oral Capsule by Glaxosmithkline LLC